CN102861185A - Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea - Google Patents
Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea Download PDFInfo
- Publication number
- CN102861185A CN102861185A CN2012103966950A CN201210396695A CN102861185A CN 102861185 A CN102861185 A CN 102861185A CN 2012103966950 A CN2012103966950 A CN 2012103966950A CN 201210396695 A CN201210396695 A CN 201210396695A CN 102861185 A CN102861185 A CN 102861185A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- traditional chinese
- blood
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea. The traditional Chinese medicine composition comprises 30g of Chinese angelica, 30g of motherwort herbs, 15g of fried cattail pollen, 10g of Sichuan lovage rhizome, 15g of flying squirrels droppings, 10g of red peony roots, 10g of cassia twigs, 10g of largehead atractylodes rhizome, 10g of Indian bread, 10g of peach kernels and 10g of red flowers, water is added into the mixture with the volume of 8 times of total weight of medical materials and 6 times of total weight of the medical materials respectively every time, the mixture is decocted and boiled for two times in the water, then filter liquids are combined, and the decompressed concentrated water is extracted. According to the application of the traditional Chinese medicine composition in preparing the drugs for treating the secondary dysmenorrheal, on the basis of differentiation and treatment theories of traditional Chinese medical science, the traditional Chinese medicine composition is formed by combining a plurality of years of clinical experience; on the basis that three parts of analgesia prescriptions before menstruation are used to treat primary dysmenorrheal, the peach kernels and the red flowers are added and have obvious curative effects in treating the secondary dysmenorrheal caused by endometriosis, adenomyosis, pelvic inflammation and the like, and particularly, the curative effect in treating the secondary dysmenorrheal caused by the endometriosis reaches 96.4%.
Description
Technical field
The invention belongs to the Chinese medicine technical field, relate to the application of Chinese medicine composition in preparation treatment secondary dysmenorrhea medicine.
Background technology
Endometriosis (EMS) is called for short gynecopathy, refers to that profit, cyclic hemorrhage appear, grow, invade in the position of endometrium beyond cavity of uterus, initiation pain, infertile and tuberosity enclosed mass etc.Its sickness rate in the women of child-bearing age and has obvious ascendant trend up to 10-15%, becomes a kind of frequently-occurring disease, difficult disease.80% EMS patient has obvious dysmenorrhea and pelvic pain, and 50% merging is sterile, has a strong impact on women's healthy and quality of life.EMS western medical treatment method is mainly divided Drug therapy and operative treatment, and Drug therapy mainly is to suppress estrogen secretion, creates the environment of a low estrogen to reach the purpose that suppresses disease progression.Though treatment energy relief of symptoms directly affects patient's endocrine function, also can affect bone metabolism, the damage liver function, unsuitable Long-term taking medicine, relapse rate is high after the drug withdrawal.The operative treatment mode is divided into radical surgery and conservative operation dealing, because EMS is mainly in the women at reproduction age, the latter is taked in operation more, and report conservative operation dealing relapse rate is up to 57.1%.Even the radical surgery that hysterectomizes also exists the pelvic cavity ectopic focus to be difficult to the problem of thoroughly removing, Postoperative recurrent rate also reaches 24.1%.Be to reduce recurrence, be aided with the treatments such as Western medicine GnRH-a, danazol after the excision focus more at present, but many patients are difficult to adhere to because of its price or side effect.Therefore, the treatment of EMS is thorny difficult problem of Gynecology always.
The EMS pathogenesis is very complicated, is the coefficient results of many factors such as environment, immunity, endocrine.EMS is as a kind of hormone-dependent diseases, its generation, development all with estrogen (E
2) close contact arranged.Studies show that, stick-attack-angiogenesis is the plantation of endometrial cell success dystopy, and the basic pathology process of pathological changes occurs.In this process, estrogen plays an important role.Traditional view thinks, endometrium is the target organ of ovarian secretion steroid hormone, only has its effect of estrogen competence exertion by the endocrine mechanism secretion, that is: no matter be ovarian secretion or fatty tissue synthetic, have the E in the circulation only
2Be transferred to the effect of target organ competence exertion.But research in recent years is found, E in EMS women and the normal women body
2Level is without significant difference, and E in the former menstrual blood
2Concentration obviously raises, and it is unusual that molecules has occured the endometrium (comprising in place, Ectopic Endometrium) that EMS patient is described, has possessed the ability of synthetic estrogen, and this may be the initiating agent that gynecopathy occurs.This has explained that also why 80% the women of child-bearing age exist menses adverse current phenomenon, and only has 10%-15% that EMS occurs.Estrogen is a kind of very strong mitogen, can increase the synthetic of endometrial stroma cell VEGE, excite the paracrine cell factor, stimulate the expression of matrix metalloproteinase (MMPs) gene, and the adhesion of VEGF, MMPs and Ectopic Endometrium, invasion and attack and angiogenesis are closely related.The endo cell that possesses secretion characteristic enters pelvic cavity with the menses of adverse current, produce E2 by autocrine and paracrine mode and be combined with self estrogen receptor, bring into play direct biological action, finish in Intrapelvic adhesion, invasion and attack, plantation, generate capillary network, progressively grow into ectopic focus.Can think, EMS ectopic endometrium internal film tissue is keys that ectopic focus is constantly grown by self secreting E2 at the high estrogen environment of part achievements.In recent years, clear gradually to the understanding of EMS ectopic focus autocrine mechanism, the estrogen synthesis approach take aromatase P450 as rate-limiting enzyme plays a leading role.
EMS belongs to the traditional Chinese medical science " dysmenorrhea ", “ mass in the abdomen ", the category of " infertile ".Chinese medicine research thinks, the morbidity of endometriosis mainly is that damaged by excess of seven emotions or wind and cold are fought mutually, makes stagnation of blood stasis, and with the passing of time blood circulating out of vessels gathers and do, and qi depression to blood stasis, blood stasis due to qi deficiency are main mechanism.Treatment is from animal economy, QI and blood regulating, and Yin Yang balancing is according to Therapeutic Principle such as blood circulation promoting and blood stasis dispelling, depressed liver-energy dispersing and QI regulating, hard masses softening and resolving, adjustment immunologic functions.After the seventies in last century, along with modern medicine going deep into EMS understanding, traditional Chinese medical science scholar also with primary disease as one independently disease carried out extensively from aspects such as etiology and pathogenesis, therapy and formulas and gradually deep research, nineteen ninety is defined as syndrome of blood stasis with this disease in the Chinese combination of Chinese and Western medicine diagnosis and treatment standard that formulate in Xi'an.Cyclic hemorrhage occurs in the endometrium of EMS dystopy under the effect of ovarian hormone, hemorrhage accumulating in the part becomes " blood circulating out of vessels ", i.e. blood stasis.Blood-stasis internal-depression vessels of the uterus, collaterals of the uterus, hematogenous blockage, stagnation of QI and blood may bring about pain are sent out and are dysmenorrhea; Blood stasis is stagnated punching and is appointed, and old blood does not go, and fresh blood is not given birth to, and can cause menoxenia, and is infertile etc., and stasis blocking is Jie Wei mass in the abdomen enclosed mass with the passing of time then.Pathogenesis of blood stasis for EMS, it is fundamental law treatment EMS that the clinicist uses blood circulation promoting and blood stasis dispelling more, adopt single medicinal material, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, cycle therapy and inside and outside the multiple Chinese traditional treatment method such as rule together, at alleviating pain, regulating menstruation and assisting pregnancy, the aspect such as improve the quality of living certain advantage is arranged all, Chinese traditional treatment does not affect the normal menstrual cycle of patient and becomes pregnant, and more is subject to numerous welcomes that have fertility to require the patient.
Summary of the invention
The present invention is on Traditional Chinese Medicine determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs theoretical basis, forms in conjunction with clinical experience for many years.Find in the long-term clinical practice that this prescription can be used for the secondary dysmenorrhea that is caused by endometriosis, uterine adenomyosis, pelvic inflammatory disease etc., particularly endometriosis is caused that secondary dysmenorrhea is evident in efficacy.
The method passes through to intervene estradiol-oxytocin receptor-uteri excitation adjusting path, suppresses uterine contraction, the regulation and control prostaglandin level, thus alleviate or elimination dysmenorrhea symptom.Under the prerequisite that reduces hypothalamus-hypophysis cerebri-hypothalamic pituitary ovarium axis gonadal hormone periodic adjustment impact, it is to cure endometriotic key that medicine directly acts on target organ, be namely to begin medication luteal phase more can alleviate interference to the feedback effect of thalamus-hypophysis cerebri-hypothalamic pituitary ovarium axis gonadal hormone in the estrogen and progestogen peak period than continuous use, effectively regulate hormonal readiness, be the best period for the treatment of endometriosis, provide a kind of new prescription for developing the effective secondary dysmenorrhea of curing of taking medicine a kind of luteal phase.
For achieving the above object, the invention discloses following technical scheme:
The application of Chinese medicine composition in preparation treatment secondary dysmenorrhea medicine; Described Chinese medicine composition is Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g add 8 times, the 6 times volumes that water is respectively the medical material gross weight at every turn, merging filtrate after decocting boils 2 times, the water extraction liquid of concentrating under reduced pressure.
Another preferred version is the application of Chinese medicine composition in the dysmenorrhea medicine that preparation treatment endometriosis, flesh gland disease, pelvic inflammation cause; Described Chinese medicine composition is Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10 g, Flos Carthami 10g, add 8 times, the 6 times volumes that water is respectively the medical material gross weight, merging filtrate after decocting boils 2 times, the water extraction liquid of concentrating under reduced pressure at every turn.
The present invention further discloses the preparation method of Chinese medicine composition, it is characterized in that being undertaken by following step:
Get above-mentioned medical material and clean remove impurity, dry, extracting in water twice adds 8 times, the 6 times volume merging filtrates that water is respectively the medical material gross weight at every turn, and concentrating under reduced pressure water extraction liquid adds appropriate amount of auxiliary materials and granulates, and makes solid preparation or liquid preparation.
The mechanism of used each Chinese crude drug of the present invention is:
Reuse Chinese angelica blood supplementing and be monarch, tonifying for deficiency syndrome; Minister is with Rhizoma Chuanxiong, Herba Leonuri promoting the circulation of blood, and it has a surplus row, the effect that the monarch and his subjects' compatibility enhancing nourishing and enriching blood and blood relieve the pain.Assistant is with Pollen Typhae, Oletum Trogopterori blood circulation promoting and blood stasis dispelling, Semen Persicae, Flos Carthami blood stasis dispelling row stagnation pain, Radix Paeoniae Rubra desilting regulating blood flow to alleviate pains; Make with the Cortex Cinnamomi temperature and lead to, slow its contracture, the Rhizoma Atractylodis Macrocephalae, Poria are transferred the property of medicine and taste.Full side's reinforcement and elimination in combination, the logical benefit of temperature let out and usefulness, invigorates blood circulation, logical blood, promoting the circulation of blood, purifies the blood, enriches blood and all medicines of blood share, and plays altogether the effect of " row stagnation pain ".Shown effect with menstrual cycle by the secondary dysmenorrhea dysmenorrhea that endometriosis causes, particularly comparatively obvious in premenstrual and menstrual, because before and after menstrual period or menstrual period, punching appoints QI and blood to change, the sea of blood overflows by completely being full of and lets out, QI and blood is by containing in fact and rapid empty, and punching is appointed, the variation of uterus QI and blood is hurried, easily forms the pathomechanism of disorder of QI and blood.Therefore, according to the growth and decline variation of menstrual cycle yang blood and qi, take the square medicine of " the stagnant regulating blood flow to alleviate pains of row " method to treat primary disease opportunity in suitable treatment, to obtain curative effect.
According to modern pharmacological research, Radix Angelicae Sinensis can suppress platelet to be built up, and antithrombotic forms; Rhizoma Chuanxiong can improve microcirculation, and blood viscosity lowering improves fibrinogen activity; Semen Persicae has inhibitory action by reducing platelet count, suppress platelet function, suppress inside and outside coagulation function, promoting fibrinolytic etc. to body thrombosis; Flos Carthami, Radix Paeoniae Rubra have the effect of analgesia, antiinflammatory, reduction Adherence of Platelet.All medicines share has the change hemorheological property, accelerates blood flowing speed, reduces whole blood viscosity, improves microcirculatory effect, thereby plays the effect that improves body blood stasis state.
The Chinese medicine composition for the treatment of secondary dysmenorrhea of the present invention and pharmaceutically acceptable carrier are mixed and made into oral formulations or injection.Described oral formulations is tablet, granule, buccal tablet, capsule or oral liquid; Injection is subcutaneous injection or intravenous injection.For example pharmaceutical composition can closely be mixed to prepare pharmaceutical composition of the present invention with active component with pharmaceutically suitable carrier according to the conventional medicine preparation technique, this carrier can adopt extensively various dosage form according to the form that is used for administration of wanting.
When the compositions of preparation peroral dosage form, any common drug medium all can use.Therefore for oral liquid such as suspension, elixir and solution, suitable carrier and additive comprise water, ethylene glycol, oil, ethanol, flavoring agent, antiseptic, stabilizing agent, coloring agent etc.; For oral solid formulation such as powder, capsule, buccal tablet, soft capsule and tablet, suitable carrier and additive comprise starch, sucrose, diluent, granulating agent, lubricant, binding agent, disintegrating agent etc.Suitable binding agent comprises, is not limited to starch, gelatin, natural sugar such as glucose or beta lactose, Semen Maydis sweetener, natural and synthetic glue such as arabic gum or enuatrol, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride etc.Disintegrating agent comprises, is not limited to starch, methylcellulose, agar, Bentonite, xanthan gum etc.Because be easy to administration, the Tablet and Capsula agent represents the oral presented in unit dosage form of most convenient, obviously uses the solid medicinal carrier in such situation.If necessary, tablet can pass through standard technique sugar coating or enteric coating.
The every dosage unit of pharmaceutical composition of the present invention for example sheet, capsule, powder, injection etc. should comprise the essential effective ingredient amount that discharges aforesaid effective dose.The every dosage unit of pharmaceutical composition of the present invention for example sheet, capsule, powder, injection, buccal tablet etc. should comprise approximately 1～1000 mg, preferably approximately 10～500 mg and approximately 0.001～5.0 mg/kg/day, preferred approximately 0.01～0.5 mg/kg/day.Yet dosage can change according to the severity of experimenter's needs, the disease for the treatment of and the chemical compound of use.Administration every day or all after date increments can use.Those skilled in the art can easily determine the ideal occlusion pharmaceutical quantities, and these dosages will be along with the progress of concentration, mode of administration and the disease disease of the extract of concrete use, mode of administration, preparation and change.The factor relevant with the concrete patient who treats comprises that patient age, body weight, diet and administration time can cause needs to adjust dosage in addition.
The Chinese medicine composition for the treatment of secondary dysmenorrhea disclosed by the invention has following characteristics:
(1) Radix Angelicae Sinensis and Rhizoma Chuanxiong strengthen and to nourish blood, to invigorate blood circulation and the power of blood in the prescription of the present invention; Herba Leonuri bitter in the mouth, cold in nature and slide plays and transfers cold and heat and QI and blood get final product, reduces in case the fraud of cold accumulating in meridian.Ramulus Cinnamomi has the merit that strengthens promoting the flow of QI-blood by warming the meridian, conducting fire back to its origin in the prescription.Simultaneously prescription is take QI and blood regulating as main, and the types such as the various dysmenorrheas of cold and heat and asthenia and sthenia such as kidney qi loss, deficient qi and blood, qi depression to blood stasis, cold blood stasis, damp-heat accumulation are all obtained satisfactory effect.
(2) prescription therapeutic of the present invention reaches 96.4% by the secondary dysmenorrhea clinical efficacy that endometriosis causes, modern pharmacology studies show that: the endometriosis patients Ectopic Endometrium can show MMP-9 and express enhancing.Its pharmacological evaluation is as follows:
1 experimental technique
1.1 the ELISA method detects the prescription Contained Serum to the impact of endometrium ectopia patient endometrial stromal cell secretion MMP-9
The stromal cell of selecting the endometriosis patients Normal endometrium of separation and Culture success is experimental group, organizes in contrast with factor palace muscular tumor row Colposcopy patient's Normal endometrium stromal cell.With the Interstitial cell cultivated respectively with 5 * 10
5/ ml concentration is inoculated in the porous culture plate, behind the cultivation 24h, and cell attachment, will normally reach the endometriosis Interstitial cell and be divided into respectively blank group: final concentration is the culture fluid of 15% normal rabbit serum.
1 group in Chinese medicine: final concentration is the culture fluid of 5% Contained Serum;
2 groups in Chinese medicine: final concentration is the culture fluid of 10% Contained Serum;
3 groups in Chinese medicine: final concentration is the culture fluid of 15% Contained Serum;
Establish 2 multiple holes for every group, add collecting cell culture fluid and cell behind the different tested factor 24h, carry out (Chinese medicine 1 wherein by ELISA test kit description, 2,3 groups are: Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g, add 8 times, the 6 times volumes that water is respectively the medical material gross weight at every turn, after decocting boils 2 times, merge the water extraction liquid of concentrating under reduced pressure).
1.2 the RT-PCR method detects the impact that prescription is expressed endometrial tissue MMP-9 mRNA
Adopt autografting to set up the endometriosis rat model, get 40 of the rats of modeling success, be divided at random model group, Chinese medicine high dose group, low dose group, gestrinone group, 10 every group, other establishes 10 of rats in sham-operated groups.Each organizes rat gastric infusion every day (or distilled water) once, and the administration capacity is 10 mL/kg, continuously 30d.Fasting 12 h after the last administration, abdomen is opened in anesthesia, quick clip ectopic endometrium tissue, sham-operation clip Normal endometrium tissue, with the aluminium-foil paper sealed envelope of high temperature enzyme denaturing ,-80 ℃ are frozen.Adopt the RT-PCR method to detect.
2 experimental results
2.1 the prescription Contained Serum is on the impact of endometrium ectopia patient endometrial stromal cell secretion MMP-9
Get blank group in the gynecopathy group and prescription 1,2,3 groups of cell culture supernatants of cultivating 24 hours, 48 hours, 72 hour three time periods, detect respectively the secretory volume of its MMP-9.
The result: 24 little periods, 48 little periods, 72 little periods, blank group and prescription 1,2,3 groups compare Analysis of variance F(24h)=2515.123,
P＜0.01, F(48h)=2922.241,
P＜0.01, F(72h)=3831.784,
P＜0.01, difference all has significance, can think that three period prescription Contained Serums have inhibitory action to the gynecopathy patient's of In vitro culture endometrial stromal cell secretion MMP-9, and along with the rising inhibitory action of prescription drug serum concentration is more obvious.
The comparison of blank group and Chinese drug-treated group different time sections secretion MMP-9 content (
± s) (n=6)
pg/mL
2.2 the impact on endometrial tissue MMP-9 mRNA expression
The expression that the model group ectopic endometrium of rats is organized MMP-9 mRNA apparently higher than sham operated rats (
P＜0.01).The expression that each dosage group of prescription and gestrinone group ectopic endometrium of rats are organized MMP-9 mRNA than model group significantly reduce (
P＜0.01).The results are shown in accompanying drawing 1.
Two, clinical trial:
Endometriosis is hormone-dependent diseases, and the research of relevant Drug therapy is to carry out with hormone medicine mostly, although this class medicine has certain therapeutic effect, and erious adverse reaction, unsuitable long-term taking.On the basis for the treatment of primary dysmenorrhea, receive preferably curative effect according to the EMS patient that is used for the treatment of of the development of clinical experience for many years, the existing report of summing up is as follows.
From year June in June, 2005-2009, inventor herein Fang Ling observes case and is in Tianjin Central Obstetrical ﹠ Gynecologist Hospital's TCM Gynecology outpatient service and Tianjin University Of Traditional Chinese Medicine's Baokang hospital admission system disease with secondary dysmenorrhea patient's 84 examples that we's treatment is caused by endometriosis.The EMS patient who adopts.Selected patient did not use the medicine of hormones and other treatments EMS in half a year, and got rid of and suffer from other immunity system Self-control method.Patient's mean age is (34.65 ± 6.11) year; Course of disease average out to (4.56 ± 2.88) year; Comprise among the 84 routine patients: 24 examples that dysmenorrhea is slight, moderate 37 examples, severe 23 examples (by the dysmenorrhea symptom score: integration is in slight, the 8-14 minute moderate below 8 minutes, severe more than 14 minutes), infertile 22 examples, pelvic cavity tenderness tuberosity 26 examples, rectal tenesmus 22 examples, aberrant ovary cyst 32 examples.
3 months courses for the treatment of, followed up a case by regular visits to 1 year, observe clinical symptoms, ultrasound diagnosis lesion volume, untoward reaction.The result shows: lesion volume dwindles, and difference has significance before and after the treatment.Patient's 84 examples were treated 3 months through we, clinical dysmenorrhea curative effect 96.4%, and (21 examples of fully recovering account for 26.2%; Produce effects 28 examples account for 33.3%; Effective 32 examples account for 38.1%; Invalid 3 examples account for 3.6%); Pregnant 18 people after the treatment, infertile curative effect 81.9%; Pelvic cavity tenderness tuberosity 19 people that disappear, curative effect 73.1%; Rectal tenesmus sense 18 people disappear, curative effect 81.8%; Aberrant ovary cyst curative effect 68.9%.Without significantly untoward reaction.In " new Chinese medicine guideline of clinical investigations " that the diagnostic criteria of MethodsThe cases enrolled canonical reference is issued with reference to Ministry of Health of the People's Republic of China in 1993 " guideline of clinical investigations of new Chinese medicine treatment endometriosis of pelvis " and formulate, and through clinical gynecologial examination, B ultrasonic, peritoneoscope and operation and pathology.Curative effect determinate standard is decided according to " guideline of clinical investigations of new Chinese medicine treatment dysmenorrhea ".Clinical recovery: the rear stomachache of taking medicine and other transference cures, the disease integrated value reduces 〉=95%, or pregnant person in 3 years.Pelvic lump disappears substantially.Produce effects: the symptoms such as the rear stomachache for the treatment of obviously alleviate, and integration is down to front below 1/2 of integration for the treatment of, and enclosed mass dwindles (the same time inspection contrast of menstrual cycle more than 1/2; B is super to check that the treatment front and back same time contrasts).Though local sign exists, infertile patient is become pregnant.Effectively: stomachache waits the sx↓ integration to be down to the front integration 1/2～3/4 for the treatment of after treating, and enclosed mass dwindles (the same time inspection contrast of menstrual cycle more than 1/3; B is super to check same time contrast before and after the treatment), symptom does not increase the weight of in the drug withdrawal 3 months.Invalid: without significant change, local patholoic change had the trend of increasing the weight of before symptom, sign were treated.The long-term observation treatment is carried out by a definite date 1 year follow up a case by regular visits to some patients were.Follow up a case by regular visits to the patient and recur without example, have 10 routine produce effects to transfer recovery from illness to, 2 examples effectively transfer produce effects to, and 2 examples are invalid to be transferred to effectively.The long-term taking no side effects does not find to cause the change of liver, renal function.So this medicine is a kind of safe and effective medicine that the secondary dysmenorrhea that is caused by endometriosis is treated in treatment, is worth further research and development.
The clinical observation demonstration, we's (secretory phase and premenstrua) medication luteal phase more can significantly improve patient's pain scores than menstrual cycle continuous use, and effective percentage reaches 96.4%; More can effectively suppress the endometrial propagation of dystopy, effective percentage reaches 73.1%.Under the prerequisite that reduces hypothalamus-hypophysis cerebri-hypothalamic pituitary ovarium axis gonadal hormone periodic adjustment impact, it is to cure endometriotic key that medicine directly acts on target organ, be namely to begin medication luteal phase more can alleviate interference to the feedback effect of thalamus-hypophysis cerebri-hypothalamic pituitary ovarium axis gonadal hormone in the estrogen and progestogen peak period than continuous use, effectively regulating hormonal readiness, is the best period for the treatment of endometriosis.
Three, typical case (model case corresponding be the dysmenorrhea that endometriosis or flesh gland disease or pelvic inflammation cause) clinical efficacy reaches 96.4%.
Model case 1
The patient, the Wang, the woman, 35 years old, married, teacher, first visit on July 19 in 2006.
Behind the main cause cesarean section 5 years, stomachache companion's stomach wall enclosed mass 3 years.Patient previously menstruation is still regular, and 7/23-28 days, in the amount, dysmenorrhea was obvious through front 1-2 days pain.The patient is positioned at the capable cesarean section of local hospital because of mature buttocks before 5 years, and operation process is smooth, and post-operative recovery is good.Occurred periodically pain of stomach wall wound before 3 years, occur menstrual period, through after alleviation.From laying one's hand on and incision enclosed mass diameter 2cm, enclosed mass increased to 3cm gradually in nearly 3 years.Since the morbidity spirit, appetite can, two is just normal, body weight is without significant change.Gynecologial examination: vulvovaginal is without unusually, and cervix uteri is smooth, anteversion of uterus, and normal large, in the matter, without tenderness, the double accessory district does not touch unusually.Auxiliary examination: abdominal ultrasonic: uterus 5.0*4.3*3.8 centimetre, flesh layer echo is even, and inner membrance is smooth, and be placed in the middle, thick 0.6 centimetre, echo is even, and left ovary 2.6*2.0 centimetre, size and form is normal, internal structure is clear, and right ovary 3.4*1.8 centimetre, size and form is normal, and internal structure is clear.Pelvic cavity has no free opaque dark area of fluid, and in the visible 3.1*3.2*1.2cm low echo-level mass of left side hypogastric region subcutaneous tissue shadow, owe clearly on the border, and it is even that internal echo is owed.
History of past illness: deny the chronic disease histories such as heart disease, hypertension, diabetes; Deny that hepatitis B, tuberculosis etc. infect medical history; Deny wound blood transfusion history.Deny food, drug allergy history, deny the long-term prescription history.
Treatment: we use three menstrual cycle continuously at Women Administered in Luteal Phase, and stomachache obviously disappears before and after menstrual period, and B ultrasonic shows, the visible 1.1*1.2*0.6cm low echo-level mass of left side hypogastric region subcutaneous tissue shadow.Three menstrual cycle that continue to take medicine, pain disappears, and B ultrasonic shows that left side hypogastric region subcutaneous tissue low echo-level mass shadow disappears, and follows up a case by regular visits to 1 year, recurrence.
Model case 2
The patient, Huang, the woman, 31 years old, married, JIUYUE in 2007 first visit on the 5th.
The main suit: dysmenorrhea, first and second day of menstrual cycle phase suffers from abdominal pain obviously, and menstrual cycle later stage stomachache does not subtract, and with the pelvic cavity chronic pain, pain continues 6 months at least.Follow the nausea and vomiting pale complexion, taking the ibuprofen modified release capsule analgesic can't alleviate, and pain appears in sexual life, and 2 years after marriage are not conceived.Through ultrasonic examination uterus normal size, the skilful capsule of bilateral ovaries, 3*3CM right side, left side 4*3CM.Can make a definite diagnosis endometriosis.
Treatment: serve on three menstrual cycle in top, took 14 to 16 doses on the 14th day in menstrual cycle, pain disappears, ultrasonic examination uterus normal size, the skilful capsule of bilateral ovaries, 1.4*1.5CM right side, left side 2*1.4CM.Three menstrual cycle that continue to take medicine, pain disappears, and it is clear that B ultrasonic shows that bilateral ovaries shows, and normal in size was followed up a case by regular visits to 1 year, recurrence.
Model case 3
The patient, in certain, the woman, 31 years old, married, civil servant, first visit on April 22 in 2009.
Menstrual period, lower abdomen enclosed mass companion pain was 3 years.3 years causes are because of the capable cesarotomy of breech presentation, and postoperative wound 1/ first heals.Menstruation in 3rd month puerperal is risen, and falling pain under the sense lower abdomen operative incision place disappears after menstruation is clean.A later each menstrual onset inferior belly gas pain and little enclosed mass is arranged, swollen thing is gradually grown up, and menstrual period, the stomach wall wound pain gradually increased the weight of.Later on whenever menstrual onset lower abdomen wound pain just occurs and carrying out property increases the weight of.Look into: ordinary circumstance is good, and abdomen is smooth, and lower abdomen incision hypomere has an enclosed mass 5cm * 4cm * 4cm size, and matter is hard, and inertia has tenderness matter hard, and is movable not good enough.
Diagnosis: stomach wall implanting endometriosis.
Treatment: serve on three menstrual cycle in top, took 14 to 16 doses on the 14th day in menstrual cycle, pain disappears, ultrasonic examination uterus normal size, and lower abdomen incision hypomere enclosed mass is contracted to 2cm * 2cm * 1cm size.Three menstrual cycle that continue to take medicine, pain disappears, and B ultrasonic shows the uterus normal size, and bilateral ovaries shows clear, normal in size, lower abdomen incision enclosed mass disappears, without touching a tender spot.Followed up a case by regular visits to 1 year, not recurrence.
The result in clinical application of Chinese medicine composition of the present invention shows:
1. the present invention is all effective in cure to the treatment of secondary dysmenorrhea and prevention, takes medicine in luteal phase and can effectively suppress the generation of dysmenorrhea, and the endometrial propagation of dystopy, has rapid-action, taking convenience, Time of Administration is short, thoroughly eradicates the characteristics of the cause of disease.
2. pectin, protein, glucose, organic acid, fructose, multivitamin, aminoacid, the required trace element of volatilization wet goods various human body are rich in the present invention, are conducive to absorption of human body, health invigorating.
3. each component of Chinese herbal medicine of the present invention meets the regulation of " the Drug Administration Law of People's Republic of China ".
Description of drawings:
Fig. 1 is the impact that prescription is expressed endometrial tissue MMP-9 mRNA.
The specific embodiment
Below in conjunction with embodiment the present invention is described, the scheme of embodiment described here, do not limit the present invention, one of skill in the art can make improvements and change according to spirit of the present invention, described these improvement and variation all should be considered as within the scope of the invention, and scope of the present invention and essence are limited by claim.Used Chinese crude drug is all on sale.
Embodiment 1
Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g adds 8 times, the 6 times volumes that water is respectively the medical material gross weight at every turn, after decocting boils 2 times, and merging filtrate, concentrating under reduced pressure water extraction liquid is divided into two bags, every bag of 100mL to 200mL, 1 bag/time, 2 times/d, oral, take the 3-5 agent through front 3-5d, extremely through damp first day, 3 menstrual cycle are a course for the treatment of.
Embodiment 2:
Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g adds 8 times, the 6 times volumes that water is respectively the medical material gross weight, after decocting boils 2 times at every turn, merging filtrate, concentrating under reduced pressure water extraction liquid, mixing, sieve, again with starch 300g mix homogeneously, with starch slurry (get starch 220g water and make starch slurry) granule processed, sieve, drying, encapsulated.
Embodiment 3:
Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g adds 8 times, the 6 times volumes that water is respectively the medical material gross weight at every turn, after decocting boils 2 times, and merging filtrate, concentrating under reduced pressure water extraction liquid adds distilled water, stirring and dissolving to 35ml, sucrose is an amount of, and adding distil water stirs to 1000ml again, filter, with filtrate fill under aseptic condition, every 5ml sealing namely gets oral liquid.
After the preferred embodiment that describes in detail, being familiar with this technology personage can be well understood to, can carry out various variations and modification not breaking away under above-mentioned claim and the spirit, all foundations technical spirit of the present invention all belongs to the scope of technical solution of the present invention to any simple modification, equivalent variations and modification that above embodiment does.And the present invention also is not subject to the embodiment that gives an actual example in the description.
Claims (2)
1. the application of Chinese medicine composition in preparation treatment secondary dysmenorrhea medicine; Described Chinese medicine composition is Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g add 8 times, the 6 times volumes that water is respectively the medical material gross weight at every turn, and decocting boils the water extraction liquid that merges afterwards concentrating under reduced pressure for 2 times.
2. the application of Chinese medicine composition in the dysmenorrhea medicine that preparation treatment endometriosis, flesh gland disease, pelvic inflammation cause; Described Chinese medicine composition is Radix Angelicae Sinensis 30g, Herba Leonuri 30g, Pollen Tyjphae (parched) 15g, Rhizoma Chuanxiong 10g, Oletum Trogopterori 15g, Radix Paeoniae Rubra 10g, Ramulus Cinnamomi 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Semen Persicae 10g, Flos Carthami 10g, add 8 times, the 6 times volumes that water is respectively the medical material gross weight, decocting boils the water extraction liquid that merges afterwards concentrating under reduced pressure for 2 times at every turn.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103966950A CN102861185A (en) | 2012-10-18 | 2012-10-18 | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103966950A CN102861185A (en) | 2012-10-18 | 2012-10-18 | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102861185A true CN102861185A (en) | 2013-01-09 |
Family
ID=47440500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103966950A Pending CN102861185A (en) | 2012-10-18 | 2012-10-18 | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861185A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161910A (en) * | 2014-05-29 | 2014-11-26 | 陈玉莲 | Traditional Chinese medicine for treating dysmenorrhea |
| CN104383060A (en) * | 2014-12-08 | 2015-03-04 | 成都锦汇科技有限公司 | Oral solution prepared from herba leonuri |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772156A (en) * | 2005-10-17 | 2006-05-17 | 李亚萍 | Chinese herbal medicine decoction for treating vital energy stagnation and blood stasis type endometriosis and its prepn |
-
2012
- 2012-10-18 CN CN2012103966950A patent/CN102861185A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772156A (en) * | 2005-10-17 | 2006-05-17 | 李亚萍 | Chinese herbal medicine decoction for treating vital energy stagnation and blood stasis type endometriosis and its prepn |
Non-Patent Citations (3)
| Title |
|---|
| 张凯等: "中医药治疗痛经近况", 《中国中医药现代远程教育》 * |
| 方玲等: "经前三剂止痛方治疗原发性痛经疗效观察", 《中华中医药学刊》 * |
| 方玲等: "经前三剂止痛方治疗实验性痛经模型大鼠作用机制研究", 《天津中医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161910A (en) * | 2014-05-29 | 2014-11-26 | 陈玉莲 | Traditional Chinese medicine for treating dysmenorrhea |
| CN104383060A (en) * | 2014-12-08 | 2015-03-04 | 成都锦汇科技有限公司 | Oral solution prepared from herba leonuri |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101884770A (en) | Chinese medicinal preparation for treating urolithiasis and preparation method thereof | |
| CN101433654B (en) | Chinese medicine preparation for treating women's chronic pelvic inflammatory disease and preparation method thereof | |
| CN101322820A (en) | Chinese medicine compound composition for treating gynecology hysteromyoma and pelvic inflammation mass | |
| CN100558394C (en) | A kind of Chinese medicine composition is used to prepare the medicine for the treatment of endometriosis | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN103977362A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and early-stage breast cancer | |
| CN101569738A (en) | Plaster for treating mastitis, hyperplasia of mammary glands, breast lumps, join thydrops, traumatic injury, preparation method and application thereof | |
| CN102973677A (en) | Traditional Chinese medicine for treating ovarian cyst | |
| CN105797046A (en) | Traditional Chinese medicine composition for uterine fibroid treatment and postoperative nursing | |
| CN102861185A (en) | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea | |
| CN102038761A (en) | Medicament for treating rheumatoid diseases | |
| CN104740536A (en) | Pharmaceutical composition for treating endometriosis (EMT) and adenomyosis (AM) and preparation method and use thereof | |
| CN102526620B (en) | Traditional Chinese medicinal composition for treating gynecological inflammation and application of same | |
| CN103585573A (en) | Oral medicine for treating hysteromyoma | |
| CN103446500A (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN103157062A (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN106421666A (en) | Pharmaceutical composition for treating liver depression and kidney deficiency type premature ovarian failure | |
| CN106214828A (en) | A kind of Chinese medicine of passage, nourishing blood and preparation method thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN105833209B (en) | Traditional Chinese medicine composition for treating endometriosis | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN104623209B (en) | A kind of Chinese medicine preparation for the treatment of kidney deficiency blood stasis type postmenopausal osteoporosis | |
| CN1292764C (en) | Chinese medicinal pill for treating postpartum disease and gynecopathy | |
| CN103223034A (en) | Traditional Chinese medicine for treating endometriosis | |
| CN101972306B (en) | Chinese medicinal capsule for treating chronic pelvic inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Fang Ling Inventor after: Jiang Guoyun Inventor after: Pu Baochan Inventor after: Dai Na Inventor before: Fang Ling |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FANG LING TO: FANG LING JIANG GUOYUN PU BAOCHAN DAI NA |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130109 |